Xponance Inc. Has $234,000 Stock Holdings in Twist Bioscience Corporation (NASDAQ:TWST)

Xponance Inc. raised its stake in Twist Bioscience Corporation (NASDAQ:TWST) by 22.0% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,953 shares of the company’s stock after acquiring an additional 1,072 shares during the period. Xponance Inc.’s holdings in Twist Bioscience were worth $234,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Farther Finance Advisors LLC lifted its stake in shares of Twist Bioscience by 18.5% in the 1st quarter. Farther Finance Advisors LLC now owns 6,435 shares of the company’s stock valued at $251,000 after purchasing an additional 1,006 shares during the period. GAMMA Investing LLC grew its holdings in Twist Bioscience by 6,499.1% during the first quarter. GAMMA Investing LLC now owns 29,366 shares of the company’s stock valued at $1,153,000 after purchasing an additional 28,921 shares during the period. Wealth Enhancement Advisory Services LLC purchased a new stake in shares of Twist Bioscience during the first quarter worth $396,000. SG Americas Securities LLC purchased a new stake in shares of Twist Bioscience in the first quarter worth $893,000. Finally, Vanguard Group Inc. raised its position in shares of Twist Bioscience by 3.4% in the fourth quarter. Vanguard Group Inc. now owns 5,807,183 shares of the company’s stock worth $269,860,000 after buying an additional 189,791 shares in the last quarter.

Analysts Set New Price Targets

TWST has been the topic of several recent analyst reports. Robert W. Baird cut their target price on Twist Bioscience from $54.00 to $44.00 and set an “outperform” rating on the stock in a research note on Tuesday, May 6th. Barclays lowered their target price on shares of Twist Bioscience from $58.00 to $45.00 and set an “overweight” rating for the company in a report on Thursday, April 10th. Guggenheim reissued a “buy” rating and set a $50.00 price target on shares of Twist Bioscience in a research report on Tuesday, May 6th. JPMorgan Chase & Co. reduced their price target on shares of Twist Bioscience from $40.00 to $33.00 and set an “underweight” rating for the company in a research report on Tuesday, May 6th. Finally, The Goldman Sachs Group reduced their price target on shares of Twist Bioscience from $55.00 to $48.00 and set a “buy” rating for the company in a research report on Tuesday, May 6th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat.com, Twist Bioscience presently has a consensus rating of “Moderate Buy” and an average target price of $50.40.

Twist Bioscience Stock Down 1.9%

TWST opened at $35.17 on Friday. Twist Bioscience Corporation has a fifty-two week low of $27.12 and a fifty-two week high of $60.90. The company has a debt-to-equity ratio of 0.03, a quick ratio of 4.24 and a current ratio of 4.51. The company has a fifty day moving average of $33.69 and a two-hundred day moving average of $39.46. The stock has a market capitalization of $2.11 billion, a price-to-earnings ratio of -10.82 and a beta of 2.41.

Twist Bioscience (NASDAQ:TWST) last released its earnings results on Monday, May 5th. The company reported ($0.66) EPS for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.10). Twist Bioscience had a negative return on equity of 33.48% and a negative net margin of 54.98%. The company had revenue of $92.79 million for the quarter, compared to analysts’ expectations of $92.00 million. On average, research analysts expect that Twist Bioscience Corporation will post -2.12 earnings per share for the current year.

Insider Transactions at Twist Bioscience

In other Twist Bioscience news, COO Patrick John Finn sold 2,800 shares of the stock in a transaction that occurred on Monday, May 5th. The shares were sold at an average price of $37.65, for a total value of $105,420.00. Following the sale, the chief operating officer directly owned 262,660 shares of the company’s stock, valued at approximately $9,889,149. This represents a 1.05% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, CFO Adam Laponis sold 2,449 shares of the stock in a transaction that occurred on Wednesday, July 9th. The shares were sold at an average price of $38.15, for a total transaction of $93,429.35. Following the completion of the sale, the chief financial officer directly owned 103,569 shares in the company, valued at approximately $3,951,157.35. This represents a 2.31% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 24,961 shares of company stock worth $877,006. 3.01% of the stock is owned by company insiders.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.